This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Super Micro stock slumps with the server maker having until Tuesday to file delayed financial accounts or risk being delisted ...

The tech-heavy Nasdaq Composite finished the volatile trading day down around 1.3%, dragged down by shares of Magnificent ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

You've probably seen the ads for GLP-1 drugs. It's a hormone that helps people lose weight, but the results are not ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Here's why TFSA investors should consider holding quality growth stocks such as HIMS and benefit from outsized gains over ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.

The report suggests compounders may be using illegally imported APIs made in unregistered overseas facilities.